Search

everythinglearnresearchcommunity

for

Search:↓

A user is waiting for pyrilutamide delivery and is seeking reviews, especially regarding side effects. No reviews have been mentioned in the conversation.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

The potential stability of pyrilutamide in a mixture with water, and how it could be used in combination with Minoxidil and Finasteride to treat hair loss.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

Hairgenetix Copper Peptide Serum and PeptideLabz GHK-Cu + AHK-Cu Serum are being compared for effectiveness in hair loss treatment. The user is seeking recommendations for other brands with authentic reviews.

The user is experiencing hair shedding of different thicknesses/lengths and is using Nizoral, ciclopirox, and pyrithione zinc conditioner. They are concerned whether the shedding is due to these treatments, miniaturization, or their low-calorie diet.

A 24-year-old male shares his two-month progress on hair regrowth using 0.5mg Dutasteride, 2.5mg Minoxidil, 10mg Biotin, and Ketoconazole shampoo, noting significant crown improvement. Users discuss the effectiveness of oral Minoxidil, with some expressing skepticism about photo angles and the necessity of Biotin unless deficient.

User shares a topical hair loss solution using melatonin and cetirizine to help reduce shedding and itching. Instructions provided for creating and using the mixture, with additional lifestyle tips for overall hair health.

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

BionicBell discussed using Bimatoprost, a medication typically for eyelash growth, for hair loss and mentioned a compounding pharmacy that can mix it with other ingredients like minoxidil and finasteride. They are seeking advice on using topical finasteride for female pattern baldness and are considering a custom foam combination to maximize hair growth results.

The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.

Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.

A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.

A user is seeking advice on mixing GHK-cu/AHK-cu with minoxidil for hair loss treatment. They are asking for recommendations on the correct mixing ratios and any experiences with copper peptides.

The conversation is about finding a reputable place to buy Clascoterone in the US. An alternative treatment, pyrilutamide, is suggested as a strong and official option.

The conversation discusses using liquid cetirizine as a topical treatment for hair loss. It mentions Minoxidil, finasteride, and RU58841 as other treatments.

The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.

Dutasteride tablets are less effective than softgel capsules because they require a fat-based environment for proper absorption. Softgel capsules, like Avodart, are designed to maximize bioavailability, while powdered tablets may result in significantly lower DHT suppression.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

A recent discovery in hair cloning identified a previously unknown cell type essential for hair follicle growth, which could potentially make lab-grown hair viable if translated to humans. However, skepticism remains due to past delays and the challenges of replicating results in humans and making the process affordable.

A user is trying to make a topical finasteride solution by crushing tablets into ethanol and glycerin but struggles with spillage. Suggestions include letting the tablets dissolve in the solution or using a pill crusher for efficiency.

The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.

Creatine use is linked to increased hair shedding for some, especially those with DHT sensitivity, but experiences vary. Some users manage hair loss with treatments like finasteride, minoxidil, or dutasteride, while others stop creatine to reduce shedding.

Dutasteride is more effective in gel capsule form due to better absorption, as it is fat-soluble. If only pills are available, taking them with fat or increasing the dose slightly may help.

The conversation discusses using microneedling with copper peptides, specifically GHK-Cu, for hair loss treatment. Some users combine it with minoxidil and topical finasteride, applying peptides either topically or through injection.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.